Oncogenic osteomalacia is caused by a small mesenchymal tumour characterised by phosphaturia, hypophosphatemia, decreased serum vitamin D3 level, and osteomalacia. Phosphaturic mesenchymal tumour of the mixed connective tissue type (PMTMCT) is the commonest subtype and usually involves a single site. We report a case of PMTMCT involving the left proximal and shaft of the tibia in a 42-year-old man.
FokAWNgTP. Osteomalacia: A case series of patients with atypical clinical orthopaedic presentations. Hong Kong Med J2010;16:476–9.
6.
HendryDSWissmanR. Case 165: Oncogenic osteomalacia. Radiology2011;258:320–2.
7.
FolpeALFanburg-SmithJCBillingsSDBiscegliaMBertoniFChoJY. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: An analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol2004;28:1–30.
8.
WeidnerNCruzSanta D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer1987;59:1442–54.
9.
De BeurSMFinneganRBVassiliadisJCookBBarberioDEstesS. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res2002;17:1102–10.
10.
WhiteKELarssonTEEconsMJ. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: Frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev2006;27:221–41.
11.
LarssonTZahradnikRLavigneJLjunggrenOJüppnerHJonssonKB. Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia. Eur J Endocrinol2003;148:269–76.
12.
PetersonNRSummerlinDJCordesSR. Multiple phosphaturic mesenchymal tumors associated with oncogenic osteomalacia: Case report and review of the literature. Ear Nose Throat J2010;89:E11–5.
13.
McGuireMHMerendaJTEtzkornJRSundaramM. Oncogenic osteomalacia. A case report. Clin Orthop Relat Res1989;244:305–8.
14.
CehreliCAlakavuklarMNCavdarCBasdemirGUndarBAkkocN. Oncogenous osteomalacia—report of a case. Acta Oncol1994;33:975–6.
15.
AvilaNASkarulisMRubinoDMDoppmanJL. Oncogenic osteomalacia: Lesion detection by MR skeletal survey. AJR Am J Roentgenol1996;167:343–5.
Reis-FilhoJSPaivaMELopesJM. Pathologic quiz case. A 36-year-old woman with muscle pain and weakness. Phosphaturic mesenchymal tumor (mixed connective tissue variant)/oncogenic osteomalacia. Arch Pathol Lab Med2002;126:1245–6.
18.
FukumotoSTakeuchiYNaganoAFujitaT. Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone1999;25:375–7.
19.
NelsonAEMasonRSRobinsonBGHoganJJMartinEAAhlströmH. Diagnosis of a patient with oncogenic osteomalacia using a phosphate uptake bioassay of serum and magnetic resonance imaging. Eur J Endocrinol2001;145:469–76.
20.
GarciaCASpencerRP. Bone and In-111 octreotide imaging in oncogenic osteomalacia: A case report. Clin Nucl Med2002;27:582–3.
21.
SeufertJEbertKMullerJEulertJHendrichCWernerE. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med2001;345:1883–8.
22.
RheeYLeeJDShinKHLeeHCHuhKBLimSK. Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy. Clin Endocrinol (Oxf)2001;54:551–4.
23.
AuethavekiatPRobertsJRBiegaTJToneyMOChristensenRSBelnapCM. Case 3. Oncogenic osteomalacia associated with hemangiopericytoma localized by octreotide scan. J Clin Oncol2005;23:3626–8.
24.
TartagliaFMinisolaSSguegliaMBlasiSBrunelliDEffettiDegli E. Tumor-induced hypophosphatemic osteomalacia associated with tertiary hyperparathyroidism: A case report. G Chir2006;27:9–13.
25.
HarishSJurriaansEJanESurMColterjohnN. Giant cell tumour of soft tissue causing oncogenic osteomalacia: Report demonstrating the use of octreotide scintigraphy in tumour localization. Clin Radiol2008;63:101–7.
26.
KimizukaTOzakiYSumiY. Usefulness of 201Tl and 99mTc MIBI scintigraphy in a case of oncogenic osteomalacia. Ann Nucl Med2004;18:63–7.
27.
BiaginiGLCoutinhoPRJonassonTHUedaCEGamaRR. Oncogenic osteomalacia: Localization of underlying peripheral tumor with 99mTc-sestamibi scintigraphy [in Portuguese]. Arq Bras Endocrinol Metabol2008;52:1505–9.
28.
DupondJLMahammediHMagyNBlagosklonovOMeaux-RuaultNKantelipB. Detection of a mesenchymal tumor responsible for hypophosphatemic osteomalacia using FDG-PET. Eur J Intern Med2005;16:445–6.
KhadgawatRSinghYKansaraSTandonNBalCSeithA. PET/CT localisation of a scapular haemangiopericytoma with tumour-induced osteomalacia. Singapore Med J2009;50:e55–7.
31.
DuetMKerkeniSSfarRBazilleCLiotéFOrcelP. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clin Nucl Med2008;33:752–6.
32.
RatanasuwanTChetsurakarnSOngphiphadhanakulBDamrongkitchaipornS. A case report of tumor-induced osteomalacia: Eight year followed-up. J Med Assoc Thai2008;91:1900–2.
